Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Secondary endpoint analyses from the trials showed 'significant improvements' in patients treated with the antibody.

LONDON, - British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such goals in response to the U.S. president's ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other best vaccine stocks to buy now. On February 24, CNBC reported that President Trump declared that ...

The post hailed “promising results” from a trial of GSK’s PARP inhibitor niraparib in brain cancer patients; the drug, sold as Zejula, is currently approved as a maintenance treatment for ...

Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90. The company’s shares opened today at p1,443. ...

The shares of GlaxoSmithKline Pharmaceuticals Ltd (GSK Pharma) jumped over 15 percent to trade at Rs 2,684 apiece on February 18, extending gains for the second straight session after releasing ...

GlaxoSmithKline share price jumped more than 17% on Tuesday and extended its surge for the third consecutive session. GlaxoSmithKline shares spiked as much as 17.69% to ₹2,744.95 apiece on the ...

GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the ...

The Food and Drug Administration on Friday gave a green light to a new meningococcal vaccine from GSK. Dubbed Penmenvy, the “5-in-1” shot is approved for people aged 10 through 25 years old and ...

Shares of GlaxoSmithKline Pharmaceuticals Ltd. are trading with gains of 20% on Monday, February 17, bucking in trend in a market where most Nifty 50 constituents are trading with losses. GSK Pharma ...